Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Sells $14,558.22 in Stock

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Director Ezra Friedberg sold 558 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $26.09, for a total transaction of $14,558.22. Following the completion of the sale, the director owned 81,042 shares of the company’s stock, valued at approximately $2,114,385.78. The trade was a 0.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pelthos Therapeutics Stock Performance

Shares of PTHS stock traded up $0.27 on Tuesday, hitting $24.60. 36,589 shares of the company’s stock traded hands, compared to its average volume of 15,341. The stock has a market cap of $85.61 million, a PE ratio of -1.19 and a beta of 3.10. The firm’s fifty day moving average is $26.73. Pelthos Therapeutics Inc. has a one year low of $16.09 and a one year high of $37.50. The company has a quick ratio of 1.86, a current ratio of 2.79 and a debt-to-equity ratio of 1.41.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($3.09) earnings per share for the quarter. The business had revenue of $10.91 million for the quarter. As a group, sell-side analysts anticipate that Pelthos Therapeutics Inc. will post -12.63 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Ikarian Capital LLC raised its position in Pelthos Therapeutics by 309.5% during the 4th quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock valued at $7,928,000 after purchasing an additional 193,307 shares during the last quarter. J. Goldman & Co LP purchased a new position in shares of Pelthos Therapeutics during the fourth quarter valued at approximately $2,418,000. Boothbay Fund Management LLC increased its stake in shares of Pelthos Therapeutics by 279.8% during the fourth quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock valued at $2,501,000 after buying an additional 59,435 shares during the period. Cantor Fitzgerald L. P. bought a new position in shares of Pelthos Therapeutics during the fourth quarter valued at approximately $1,085,000. Finally, Diadema Partners LP raised its holdings in shares of Pelthos Therapeutics by 138.1% during the fourth quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock valued at $775,000 after acquiring an additional 14,502 shares in the last quarter. Hedge funds and other institutional investors own 77.96% of the company’s stock.

Analysts Set New Price Targets

PTHS has been the subject of several analyst reports. Oppenheimer increased their target price on Pelthos Therapeutics from $62.00 to $66.00 and gave the company an “outperform” rating in a report on Friday, May 15th. Zacks Research upgraded Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 24th. HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Pelthos Therapeutics in a report on Thursday, March 19th. Finally, Cantor Fitzgerald began coverage on shares of Pelthos Therapeutics in a research note on Wednesday, April 1st. They issued an “overweight” rating and a $50.00 target price on the stock. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $55.80.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).